Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale. Read More
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 5.2% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 3.8% in the company’s quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval.
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the historic, yet short-lived, success of its Hepatitis C cures. However, as of early 2026, that narrative has shifted dramatically. Gilead has successfully executed a "second [...]
Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). The updated label reinforces the robust safety data of Yescarta in eligible patients with R/R PCNSL; Yescarta is the only CAR T-cell therapy approved for R/R large B-cell lymphoma to have this Limitations of Use removed.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer
yielding 6%, the sector remains a key volatility hedge following successful U.S. manufacturing negotiations.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
In honor of Black History Month, The Commonwealth Club, in partnership with MelanInScience, WeAre, and The Michelle Meow Show, hosts The Age of Tech x Biopharma , a powerful executive forum examining how artificial intelligence (AI) and other technologies are redefining biopharmaceutical innovation, leadership, and improving patient care.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2025 financial results and provide a business update.
